Myopia management in the Netherlands A report published in March by Caroline Klaver, Jan Polling and the Erasmus Myopia Research Group detailed a literature review of current myopia treatment options, and detailed their plan for treating children presenting to the Department of Ophthalmology and the University Medical Centre. They have developed a new protocol which factors in take age, expected …
The atropine landscape is constantly evolving as new studies are published, and it can be difficult as a clinician to make decisions about what concentrations provide the highest myopia control efficacy but lowest side effect profile for your patient. Not to mention keeping abreast of all the catchy acronyms! Here is a compiled summary of all of the most recent …
Welcome to Part 2 of the updates from the American Academy of Optometry 2019 Meeting. These updates all sprung from Mark Bullimore and Noel Brennan’s fantastic session entitled Twelve Evidence Based Things That We Should Know About Myopia. Links to Part 1 and Part 3 can be found at the end of this blog. There is little evidence that handheld …
Read MoreLatest Research: AAO2019 Part 2 – We Know What we Don’t Know
The third biannual World Congress of Optometry and meeting of the American Academy of Optometry was held in October 2019 in Orlando. The following three updates include some of the highlights to come of over 16 hours of fantastic lecture content on myopia. Addressing the global myopia burden: guest summary by Sally Dillehay The following has been edited for this …
Read MoreLatest Research: AAO2019 Part 1 – The New Facts, Figures and Futures
Whilst each individual child has their own circumstances and situation to consider when prescribing myopia control, children with astigmatism present a unique set of challenges when selecting the best option for not only slowing down the progression of their axial growth, but also providing them with good vision. Simply ignoring the astigmatism when selecting a prescribing choice runs the risk …
Read MorePrescribing for the Progressing Myope with Astigmatism
Welcome to Part 2 of the ARVO 2019 Research Roundup! For article abstracts and more info, please click on the headings. You’ll find links to Part 1 and Part 3 of the ARVO latest at the end of this blog. 1 – Atropine and the LAMP Study In the much anticipated Low-concentration atropine for myopia progression (LAMP) study Phase 2: …
Read MoreLatest Research: ARVO 2019, Part 2 – Medication Updates
Podcast summary: Professor Mark Bullimore of the University of Houston, Texas USA, tells us more on the complex topic of 0.01% atropine, including its stability as a compound, and takes us on a short journey through chemistry explaining how current studies are using novel formulations to address this issue. Have you heard of ‘heavy water’? I hadn’t, until now! Mark …
Read MoreMore on 0.01% atropine treatment for myopia management – with Prof Mark Bullimore
Podcast summary: Professor James Loughman from Technological University Dublin, and the Centre for Eye Research Ireland, challenges us to think differently about low dose atropine. What are we actually getting in the bottle? How should we approach atropine usage in practice? What will future research tell us? The message on 0.01% atropine is complex and perhaps not what you expect. …
Read MoreAtropine 0.01% for myopia management – with Prof James Loughman
This open-access continuing education article I authored was published in Australian professional journal Mivision in December 2018. It describes that while there’s a lot we know about myopia control – the imperative to reduce lifelong risk of vision impairment; that numerous options are available; and that the sooner we start the better – it is imperative for the clinician to …
Atropine has been the apparent hero of myopia management since the 2006 publication of the ATOM (atropine for the treatment of childhood myopia) study, which showed an 80% refractive and 100% axial length myopia controlling effect with 1% atropine compared to placebo.1 The significant side effects of mydriasis and cycloplegia, though, made it less than tolerable as a first line …